Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI-Driven Clinical Breakthroughs.
CRISPR-engineered neutrophil therapies show promise in early research, though major hurdles around cell persistence and safety must be solved before treating patients.
This review surveys the emerging field of engineered neutrophil therapeutics, describing how CRISPR-mediated reprogramming, nanoparticle drug delivery, and AI-driven multi-omics optimization are converging to produce novel cellular therapies. Despite promising preclinical results in cancer and autoimmune settings, significant translational barriers including short persistence, off-target edits, and immune rejection must be overcome before clinical application.
What the study was
- Study design
- Narrative/integrative review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Advanced Healthcare Materials
Why it surfaced
Useful landscape review for engineered cellular therapy space; no new primary data or clinical translation data.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.